Lubiprostone: chronic constipation and irritable bowel syndrome with constipation
- 16 December 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (1), 143-152
- https://doi.org/10.1517/14656560802631319
Abstract
Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. The FDA has approved lubiprostone for the treatment of chronic constipation in men and women and the treatment of women with irritable bowel syndrome with constipation (IBS-C). Lubiprostone specifically activates type-2-chloride channels on the apical membrane of epithelial cells. Lubiprostone acts locally within the intestinal tract, is rapidly metabolized and has very low systemic bioavailability. Animal studies have demonstrated that lubiprostone increases gastrointestinal fluid secretion in a dose-dependent manner. Clinical studies performed in men and women with chronic constipation using 24 microg of lubiprostone twice-daily demonstrated objective improvement in stool frequency and consistency, as well as symptoms of straining and incomplete evacuation. A multi-center study of patients with IBS-C found that 8 microg of lubiprostone twice-daily improved both global and individual symptoms of irritable bowel syndrome. Lubiprostone is generally well tolerated and serious adverse events are rare. The most common reported side effects are nausea, headache and diarrhea. This monograph provides a brief overview on chloride channel function in the gastrointestinal tract, describes the structure, function, and pharmacokinetics of lubiprostone, and discusses the safety and efficacy of this new medication for the treatment of chronic constipation and IBS-C.Keywords
This publication has 35 references indexed in Scilit:
- Functional Bowel DisordersGastroenterology, 2006
- Systematic Review on the Management of Chronic Constipation in North AmericaThe American Journal of Gastroenterology, 2005
- The Health-Related Quality of Life and Economic Burden of ConstipationPharmacoEconomics, 2005
- Epidemiology of Constipation in North America: A Systematic ReviewAmerican Journal Of Gastroenterology, 2004
- Health-related quality of life in functional GI disorders: focus on constipation and resource utilizationThe American Journal of Gastroenterology, 2002
- Costs of care for irritable bowel syndrome patients in a health maintenance organizationThe American Journal of Gastroenterology, 2001
- A Comparison of The Rome and Manning Criteria for Case Identification in Epidemiological Investigations of Irritable Bowel SyndromeAmerican Journal Of Gastroenterology, 2000
- U. S. Householder survey of functional gastrointestinal disordersDigestive Diseases and Sciences, 1993
- Onset and Disappearance of Gastrointestinal Symptoms and Functional Gastrointestinal DisordersAmerican Journal of Epidemiology, 1992
- Epidemiology of colonic symptoms and the irritable bowel syndromeGastroenterology, 1991